Physician profile
Yousaf Ali
NPI 1003891623
$36,490.47
in general payments reported to CMS, 2019-2025
20 companies · $5,136 in 2025
The $5,136 reported for 2025 was more than what 86% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,448 · 2020: $1,554 · 2021: $6,131 · 2022: $12K · 2023: $3,626 · 2024: $2,763 · 2025: $5,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,200 · Food and Beverage: $1,707 · Travel and Lodging: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,200.00 |
| Food and Beverage | $1,707.22 |
| Travel and Lodging | $618.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $17,554.66 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $9,407.61 | 2021-2024 | Cosentyx |
| Amgen INC. | $3,571.30 | 2019-2025 | Krystexxa, Uplizna, Evenity |
| Ucb, INC. | $1,570.58 | 2019-2025 | Bimzelx |
| Fresenius Kabi USA, LLC | $1,440.00 | 2022 | |
| Abbvie INC. | $972.58 | 2019-2025 | |
| Celltrion Healthcare Co., LTD | $500.00 | 2019 | |
| Daiichi Sankyo INC. | $380.46 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $358.00 | 2022-2025 | Saphnelo |
| Horizon Therapeutics Plc | $264.89 | 2021-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $150.44 | 2025 | Strensiq |
| Glaxosmithkline, LLC. | $72.76 | 2019-2024 | Benlysta |
| Sandoz INC. | $51.34 | 2022 | |
| Celltrion USA INC. | $41.85 | 2023 | Vegzelma |
| E.R. Squibb & Sons, L.L.C. | $40.58 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $39.96 | 2022-2023 | Olumiant, Taltz |
| Genzyme Corporation | $32.55 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.63 | 2024 | Cyltezo |
| Pfizer INC. | $14.28 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yousaf Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.